Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

← catalyst calendar

NCT03715933 · readout ≤ 865 d

Sponsored by Inhibrx Biosciences, Inc (industry) · INBX — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

411estimated

Sites

Countries

France, Italy, Netherlands +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-10-08

actual

When the study began enrolling

Primary completion

Dec 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2029

estimated

The whole study's end, after follow-up

First posted

2018-10-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Ewing Sarcoma
Colorectal Adenocarcinoma

Interventions

Drug: INBRX-109
Drug: Irinotecan
Drug: Temozolomide
Drug: carboplatin
Drug: pemetrexed
Drug: Leucovorin
Drug: Fluorouracil
Drug: Bevacizumab
Drug: Trifluridine + Tipiracil

Primary outcomes

what the primary-completion date above is the date OF

Frequency and severity of adverse events of INBRX-109

measured Up to 8 years

Evaluating Tumor Response for colorectal cancers and Ewing sarcoma

measured Up to 8 years

Publications

PMID 37265425 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INBX's whole pipeline · Catalyst calendar · Every registered study · What changed